[go: up one dir, main page]

ECSP22041864A - NEW CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINIL-10-ACETATE - Google Patents

NEW CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINIL-10-ACETATE

Info

Publication number
ECSP22041864A
ECSP22041864A ECSENADI202241864A ECDI202241864A ECSP22041864A EC SP22041864 A ECSP22041864 A EC SP22041864A EC SENADI202241864 A ECSENADI202241864 A EC SENADI202241864A EC DI202241864 A ECDI202241864 A EC DI202241864A EC SP22041864 A ECSP22041864 A EC SP22041864A
Authority
EC
Ecuador
Prior art keywords
acetate
chemical compound
new chemical
lysine
acridinyl
Prior art date
Application number
ECSENADI202241864A
Other languages
Spanish (es)
Inventor
Andrey Yurievich Petrov
Alexey Leonidovich Kovalenko
Original Assignee
Scientific Tech Pharmaceutical Firm Polysan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scientific Tech Pharmaceutical Firm Polysan Ltd filed Critical Scientific Tech Pharmaceutical Firm Polysan Ltd
Publication of ECSP22041864A publication Critical patent/ECSP22041864A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El invento se refiere a la qu?mica, la farmacia y la medicina, y en particular a un nuevo compuesto qu?mico de la clase de los derivados del 9-oxo-acridinil-10-acetato: L-lisina 9-oxo-acridinil-10-acetato, que estimula la producci?n de interleucina-24 (IL-24), y el factor de necrosis tumoral beta (TNF-?) que tiene actividad antitumoral. El invento puede utilizarse para la terapia antitumoral, en particular como coadyuvante en el tratamiento combinado de enfermedades oncol?gicas. El objetivo del invento es crear un nuevo compuesto qu?mico que estimule la producci?n de las citocinas interleucina-24 y el factor de necrosis tumoral beta, y tenga actividad antitumoral con baja toxicidad. El objetivo propuesto se realiza mediante un nuevo compuesto qu?mico: L-lisina 9-oxo-acridinil-10-acetato, representado por la f?rmula (I) o (II).The invention relates to chemistry, pharmacy and medicine, and in particular to a new chemical compound of the class of 9-oxo-acridinyl-10-acetate derivatives: L-lysine 9-oxo- acridinyl-10-acetate, which stimulates the production of interleukin-24 (IL-24), and tumor necrosis factor beta (TNF-?), which has antitumor activity. The invention can be used for antitumor therapy, in particular as an adjuvant in the combined treatment of oncological diseases. The objective of the invention is to create a new chemical compound that stimulates the production of the cytokines interleukin-24 and tumor necrosis factor beta, and has antitumor activity with low toxicity. The proposed objective is achieved by means of a new chemical compound: L-lysine 9-oxo-acridinyl-10-acetate, represented by formula (I) or (II).

ECSENADI202241864A 2019-10-29 2022-05-25 NEW CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINIL-10-ACETATE ECSP22041864A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019134800A RU2730530C1 (en) 2019-10-29 2019-10-29 New chemical compound of l-lysine 9-oxoacridinyl-10-acetate, stimulating production of interleukin-24 and tumour necrosis factor - beta

Publications (1)

Publication Number Publication Date
ECSP22041864A true ECSP22041864A (en) 2022-08-31

Family

ID=72235056

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202241864A ECSP22041864A (en) 2019-10-29 2022-05-25 NEW CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINIL-10-ACETATE

Country Status (10)

Country Link
CN (1) CN114901643B (en)
BR (1) BR112022008046A2 (en)
CO (1) CO2022007317A2 (en)
EA (1) EA035914B1 (en)
EC (1) ECSP22041864A (en)
GE (1) GEP20237566B (en)
MD (1) MD20220026A2 (en)
PH (1) PH12022551029A1 (en)
RU (1) RU2730530C1 (en)
WO (1) WO2021086234A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2326115C2 (en) * 2005-11-21 2008-06-10 Ефаг АО Salts of 1-alkylamino-1-desoxypolyols with 9-oxoacridine-10-acetic acid, medicinal preparations on their base, their use, preventive measures and treatment
RU2325160C1 (en) * 2006-07-31 2008-05-27 Ефаг АО Means of treatment and relapse prevention of prostate cancer
RU2363466C2 (en) * 2007-03-29 2009-08-10 АО Ефаг Method and set for treating and preventing malignant tumours of female reproductive system using 9-oxoacridine-10-acetic acid, and/or salt thereof and/or ester thereof
RU2346692C2 (en) * 2007-03-29 2009-02-20 Ефаг АО Application of 9-oxoacridine-10-acetic acid, its salts and esters in combined therapy for ovarian carcinoma, method of treatment and sets
EP3713920A4 (en) * 2017-11-20 2021-04-14 Silicon Swat, Inc. OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE

Also Published As

Publication number Publication date
WO2021086234A1 (en) 2021-05-06
GEP20237566B (en) 2023-11-10
BR112022008046A2 (en) 2022-07-12
RU2730530C1 (en) 2020-08-24
EA202000071A1 (en) 2020-08-28
PH12022551029A1 (en) 2023-04-24
CO2022007317A2 (en) 2022-06-21
CN114901643A (en) 2022-08-12
CN114901643B (en) 2024-06-25
EA035914B1 (en) 2020-08-31
MD20220026A2 (en) 2022-09-30

Similar Documents

Publication Publication Date Title
CY1124130T1 (en) 2,2-DIFLUOROPROPIONAMIDE DERIVATIVE OF VARDOXOLONE METHYLATE, PHARMACEUTICAL COMPOSITIONS AND POLYMORPHINES THEREOF FOR USE IN THE THERAPEUTIC TREATMENT OF SPECIFIC DISEASES
DOP2020000050A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THEM
CL2019002461A1 (en) Therapeutic rna.
ECSP18073726A (en) WDR5 PROTEIN-PROTEIN BOND INHIBITORS
CY1120866T1 (en) DNA-PK INHIBITORS
NI201600164A (en) COMPOUNDS AND COMPOSITIONS AS AGONISTS OF THE TOLL 7 TYPE RECEPTOR
MX2021006531A (en) COMPOSITION CONTAINING ARN FOR THE TREATMENT OF TUMORAL DISEASES.
ECSP20024210A (en) USE OF P38 INHIBITORS TO REDUCE THE EXPRESSION OF DUX4
NI201500161A (en) SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
NI200700296A (en) IMIDAZOQUINOLINAS AS INHIBITORS OF KINASE OF LIPIDO
GT201600010A (en) PYRROLAMIDE DERIVAODS SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS DRUGS FOR THE TREATMENT OF HEPATITIS B
ECSP13012417A (en) NAPHT-2-ILACETIC ACID DERIVATIVES TO TREAT AIDS
CO2022007814A2 (en) Tyk2 pseudokinase ligands
CL2019002079A1 (en) Pim kinase inhibitor salts; useful in the treatment of cancer. (divisional request 201800611)
CO2021007402A2 (en) Supply Constructs for Transcytosis and Related Methods
MX2022014792A (en) COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND TREATMENT METHODS INVOLVING THEM.
NI202000029A (en) SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND THEIR USE
CO2018009783A2 (en) Antibodies-anti-tnfalfa-and functional fragments thereof
BR112017014189A2 (en) cancer therapy with a parvovirus combined with bevacizumab
CO2020004984A2 (en) Process to prepare benzothiophen-2-yl boronate
ECSP22041864A (en) NEW CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINIL-10-ACETATE
CL2020000127A1 (en) Therapeutic modulators of the reverse mode of atp synthase.
CU20180044A7 (en) NEW DERIVATIVES OF DIAMINO PIRIDINA
CL2023002812A1 (en) Pharmaceutical combinations for cancer treatment
MX2021009767A (en) FMCR UNION MOLECULES AND USES THEREOF.